mepolizumab

Mon, 16 Oct 2023 16:07:36 -0400
Adolescents and children (aged 6 years and older) who are inadequately controlled with medium-to-high-dose inhaled corticosteroids and an additional asthma controller (e.g., LABA); and who have a blood eosinophil count of ≥ 150 cells/mcL (0.15 GI/L) at initiation of treatment with Nucala OR ≥ 300 cells/mcL (0.3 GI/L) in the past 12 months.